Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

Summary

The main purpose of this study is to investigate the effect of veliparib in ovarian cancer patients with known BRCA 1/2 mutations who do no longer respond to conventional chemotherapy.

Timeline

Start

2011-11

Primary completion

2016-01

Completion

2016-08

Drugs

Indications